“The industry executive said the quiet part out loud,” said one outside expert in response. “Price-gouging is central to the industry business model.”

By Andrea Germanos, staff writer for Common Dreams. Published 11-28-2019

Photo: Liz McGregor

Corporations’ quest for profits is what “is driving up drug prices and nothing more.”

That’s according to Dennis Bourdette, M.D., chair of neurology in the Oregon Health and Science University (OHSU) School of Medicine, who co-authored a study published Monday that sought to find out companies’ rationale for the escalating prices on medications for patients with multiple sclerosis. Continue reading →